Skip to main content

Advertisement

SpringerLink
Log in

In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Although the presence of physiologic anti-CD95 (Fas, APO-1) autoantibodies in intravenous immunoglobulin (IVIG) preparations is known, the effects of these antibodies in patients with common variable immunodeficiency are unclear (CVID). The aim of the study was to assess the effects of IVIG in Fas expression, activation markers and the subsets of T cells in patients with CVID. We studied 15 cases with CVID and 10 healthy controls with no signs of immunodeficiency. The Fas expression of T cells, activation markers (CD25, CD69 and HLA-DR) and T-cell subsets were analyzed by four-color flow cytometry. We found that the Fas expression of CD3+ T cells in patients was significantly higher than in controls. In addition, there was a significant increase in the Fas expression of CD3+ T cells and CD4+ T cells, and the CD25 expression of CD3+ and CD4+ T cells after IVIG supplementation (P < 0.05). The CD69 and HLA-DR expressions of T cells and CD8+ T cells were not affected by IVIG infusion. Our observation showed that IVIG replacement causes an increase in the Fas and CD25 expressions in patients with CVID. These data suggest that the Fas protein may have an important role in the effects of IVIG for the control of autoimmunity in patients with CVID, as well as in the generation of autoimmune disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lemieux R, Bazin R, Sonia N (2005) Therapeutic intravenous immunoglobulins. Mol Immunol 42:839–848

    Article  CAS  PubMed  Google Scholar 

  2. Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2003) Mechanisms of action of intravenous immunoglobulins in autoimmune and inflammatory diseases. Transfus Clin Biol 10:165–169

    Article  CAS  PubMed  Google Scholar 

  3. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755

    Article  CAS  PubMed  Google Scholar 

  4. Seite JF, Shoenfeld Y, Youinou P, Hillion S (2008) What is the content of the magic draft IVIg? Autoimmun Rev 7:435–439

    Article  PubMed  Google Scholar 

  5. Sapir T, Shoenfeld Y (2005) Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29:185–199

    Article  CAS  PubMed  Google Scholar 

  6. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456

    Article  CAS  PubMed  Google Scholar 

  7. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781–3790

    CAS  PubMed  Google Scholar 

  8. Altznauer F, Von Gunter S, Spath P, Simon HU (2003) Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112:1185–1190

    Article  CAS  PubMed  Google Scholar 

  9. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493

    Article  CAS  PubMed  Google Scholar 

  10. French LE (2006) Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 55:9–16

    Article  PubMed  Google Scholar 

  11. International Union of Immunological Societies (1999) Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol 118(suppl 1):1–28

    Google Scholar 

  12. Sewell WA, North ME, Cambronero R, Webster AD, Farrant J (1999) In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 116:509–515

    Article  CAS  PubMed  Google Scholar 

  13. White WB, Desbonnet CR, Ballow M (1987) Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia. Am J Med 81:431–436

    Article  Google Scholar 

  14. Ballow M, White W, Desbonnet C (1989) Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immunoglobulin. J Allergy Clin Immunol 84:595–601

    Article  CAS  PubMed  Google Scholar 

  15. Berlana D, Vidaller A, Jódar R, Fort E, Domingo A, Pastó L (2005) Changes in biochemical, hematological and immunological profiles after low-dose intravenous immunoglobulin administration in patients with hypogammaglobulinemia. Transfus Clin Biol 12:433–440

    Article  PubMed  Google Scholar 

  16. Conley ME, Notarangelo LD, Etzioni A (1999) Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93:190–197

    Article  CAS  PubMed  Google Scholar 

  17. Bossuyt X, Marti GE, Fleisher TA (1997) Comparative analysis of whole blood lysis methods for flow cytometry. Cytometry 30:124–133

    Article  CAS  PubMed  Google Scholar 

  18. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD (1996) Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 104(suppl 1):3–9

    CAS  PubMed  Google Scholar 

  19. Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56:661–663

    Article  CAS  PubMed  Google Scholar 

  20. Toyoda M, Pao A, Petrosian A, Jordan SC (2003) Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3:156–166

    Article  CAS  PubMed  Google Scholar 

  21. von Gunten S, Simon HU (2008) Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 7:453–456

    Article  Google Scholar 

  22. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A (1992) Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12:325–334

    Article  PubMed  Google Scholar 

  23. Van Schaik IN, Vermeulen M, Brand A (1994) In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 57:15–17

    Article  PubMed  Google Scholar 

  24. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH (1993) Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231–2235

    Article  CAS  PubMed  Google Scholar 

  25. Iglesias J, Matamoros N, Raga S, Ferrer JM, Mila J (1999) CD95 expression and function on lymphocyte subpopulations in common variable immunodeficiency (CVID): related to increased apoptosis. Clin Exp Immunol 117:138–146

    Article  CAS  PubMed  Google Scholar 

  26. Di Renzo M, Zhou Z, George I, Becker K, Cunningham-Rundles C (2000) Enhanced apoptosis of T cells in common variable immunodeficiency. Role defective CD28 costimulation. Clin Exp Immunol 120:503–511

    Article  CAS  PubMed  Google Scholar 

  27. Di Renzo M, Serrano D, Zhou Z, George I, Becker K, Cunningham-Rundles C (2001) Enhanced T-cell apoptosis in common variable immunodeficiency: negative role of the Fas/Fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS. Clin Exp Immunol 125:117–122

    Article  CAS  PubMed  Google Scholar 

  28. Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F (2001) Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto) antigen-specific T cells without inducing apoptosis. J Neuroimmunol 114:160–167

    Article  CAS  PubMed  Google Scholar 

  29. Wu KH, Wu WM, Lu MY, Chiang BL (2006) Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr Allergy Immunol 17:60–68

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

None of the authors has any potential financial conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Division of Immunology and Allergy, Department of Pediatrics, Selcuk University Meram Medical Faculty, Beysehir Yolu, 42080, Konya, Turkey

    Hasibe Artac, Reyhan Kara & Ismail Reisli

Authors
  1. Hasibe Artac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reyhan Kara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ismail Reisli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasibe Artac.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Artac, H., Kara, R. & Reisli, I. In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency. Clin Exp Med 10, 27–31 (2010). https://doi.org/10.1007/s10238-009-0061-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-009-0061-1

Keywords

Search

Navigation